MA41559A - Composé de pyrimidine condensé ou un sel de celui-ci - Google Patents

Composé de pyrimidine condensé ou un sel de celui-ci

Info

Publication number
MA41559A
MA41559A MA041559A MA41559A MA41559A MA 41559 A MA41559 A MA 41559A MA 041559 A MA041559 A MA 041559A MA 41559 A MA41559 A MA 41559A MA 41559 A MA41559 A MA 41559A
Authority
MA
Morocco
Prior art keywords
salt
pyrimidine compound
condensed pyrimidine
condensed
compound
Prior art date
Application number
MA041559A
Other languages
English (en)
Inventor
Hidenori Fujita
Masanori Kato
Isao Miyazaki
Tadashi Shimamura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA41559A publication Critical patent/MA41559A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA041559A 2015-09-08 2016-09-06 Composé de pyrimidine condensé ou un sel de celui-ci MA41559A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015177073 2015-09-08

Publications (1)

Publication Number Publication Date
MA41559A true MA41559A (fr) 2017-12-26

Family

ID=58239818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041559A MA41559A (fr) 2015-09-08 2016-09-06 Composé de pyrimidine condensé ou un sel de celui-ci

Country Status (20)

Country Link
US (4) US10233189B2 (fr)
EP (1) EP3260454B1 (fr)
JP (1) JP6113379B1 (fr)
KR (1) KR102058366B1 (fr)
CN (1) CN108026101B (fr)
AU (1) AU2016319525C1 (fr)
CA (1) CA2996682C (fr)
ES (1) ES2877537T3 (fr)
IL (1) IL257306B (fr)
MA (1) MA41559A (fr)
MX (1) MX390503B (fr)
MY (1) MY192184A (fr)
NZ (1) NZ739893A (fr)
PH (1) PH12017502407B1 (fr)
PL (1) PL3260454T3 (fr)
RU (1) RU2729636C2 (fr)
SG (1) SG11201800135WA (fr)
TW (1) TWI675840B (fr)
WO (1) WO2017043550A1 (fr)
ZA (1) ZA201800218B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2018322286B2 (en) 2017-08-21 2022-03-10 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
WO2019143991A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolo[3,4-d]pyrimidine substitués utilisés en tant qu'inhibiteurs de la kinase ret
WO2019143977A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrrolo[2,3-d]pyrimidines substitués utilisés en tant qu'inhibiteurs de la kinase ret
BR112020018383A2 (pt) 2018-04-05 2020-12-29 Merck Patent Gmbh Compostos heteroarílicos como inibidores da irak tipo ii e usos dos mesmos
CA3111984A1 (fr) 2018-09-10 2020-03-19 Array Biopharma Inc. Composes heterocycliques condenses comme inhibiteurs de kinases ret
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
MX2023005990A (es) * 2020-11-20 2023-06-07 Taiho Pharmaceutical Co Ltd Agente terapeutico antitumoral que migra al cerebro, que contiene como ingrediente activo un compuesto de pirimidina fusionada.
CA3234317A1 (fr) 2021-10-22 2023-12-14 Wa Xian Methodes et compositions pour traiter une lesion inflammatoire chronique, une metaplasie, une dysplasie et des cancers des tissus epitheliaux

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US5665721A (en) 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
CA2546192C (fr) 2003-11-17 2010-04-06 Pfizer Products Inc. Composes de pyrrolopyrimidine utiles dans le traitement du cancer
CN1925855B (zh) * 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
EP1797054A2 (fr) 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
EP1968979A2 (fr) * 2005-12-08 2008-09-17 Abbott Laboratories Composes heterobicycliques a neuf chainons comme inhibiteurs de proteine kinases
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
WO2013059740A1 (fr) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Nouvelles molécules de fusion alk et ntrk1 et leurs utilisations
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
EP2981613A4 (fr) 2013-02-22 2016-11-02 Boris C Bastian Polynucléotides de fusion et polypeptides de fusion associés au cancer, en particulier au mélanome, et leurs utilisations en tant que cibles thérapeutiques et diagnostiques
JP6397897B2 (ja) * 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
WO2015022926A1 (fr) 2013-08-12 2015-02-19 大鵬薬品工業株式会社 Nouveau composé pyrimidine fusionnée ou son sel
WO2015078417A1 (fr) 2013-11-29 2015-06-04 四川好医生药业集团有限公司 Composé pyrrolopyrimidine et son utilisation dans la préparation d'un médicament hypoglycémiant
JP2015205555A (ja) 2014-04-18 2015-11-19 日立オートモティブシステムズ株式会社 組込制御システム
DK3345907T3 (da) 2015-09-01 2020-06-22 Taiho Pharmaceutical Co Ltd Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo

Also Published As

Publication number Publication date
CN108026101A (zh) 2018-05-11
EP3260454B1 (fr) 2021-06-09
EP3260454A1 (fr) 2017-12-27
CN108026101B (zh) 2020-06-26
AU2016319525A1 (en) 2018-01-25
US10233189B2 (en) 2019-03-19
NZ739893A (en) 2019-07-26
US20200270260A1 (en) 2020-08-27
US20180009817A1 (en) 2018-01-11
TWI675840B (zh) 2019-11-01
KR20180042368A (ko) 2018-04-25
RU2018112252A3 (fr) 2019-10-09
US11236096B2 (en) 2022-02-01
AU2016319525B2 (en) 2019-01-31
WO2017043550A1 (fr) 2017-03-16
CA2996682C (fr) 2021-01-12
KR102058366B1 (ko) 2019-12-23
EP3260454A4 (fr) 2018-02-21
ES2877537T3 (es) 2021-11-17
PH12017502407A1 (en) 2018-06-25
MX390503B (es) 2025-03-20
JP6113379B1 (ja) 2017-04-12
US20190092776A1 (en) 2019-03-28
RU2729636C2 (ru) 2020-08-11
MX2018002889A (es) 2018-06-18
ZA201800218B (en) 2019-06-26
AU2016319525C1 (en) 2019-07-25
HK1254983A1 (zh) 2019-08-02
IL257306B (en) 2021-07-29
MY192184A (en) 2022-08-05
US10787457B2 (en) 2020-09-29
RU2018112252A (ru) 2019-10-09
JPWO2017043550A1 (ja) 2017-09-07
PL3260454T3 (pl) 2021-11-22
CA2996682A1 (fr) 2017-03-16
TW201716412A (zh) 2017-05-16
US20200270261A1 (en) 2020-08-27
BR112018000698A2 (pt) 2018-09-18
PH12017502407B1 (en) 2018-06-25
US11014930B2 (en) 2021-05-25
IL257306A (en) 2018-03-29
SG11201800135WA (en) 2018-02-27

Similar Documents

Publication Publication Date Title
MA41559A (fr) Composé de pyrimidine condensé ou un sel de celui-ci
ZA201905332B (en) Novel condensed pyrimidine compound or salt thereof
EP3381896A4 (fr) Nouveau composé de biphényle ou un sel de celui-ci
EP3360864A4 (fr) Composé pyrimidine
MA50466A (fr) Nouveau composé de biphényle ou sel de celui-ci
MA45185A (fr) Composé de sulfonamide ou son sel
EP3327019A4 (fr) Composé hétérocyclique
EP3372604A4 (fr) Composé hétérocyclique condensé
EP3354638A4 (fr) Composé de phtalonitrile
EP3372588A4 (fr) Composé de pyrimidine
EP3299355A4 (fr) Composé de phtalonitrile
EP3381916A4 (fr) Composé pyrimidine condensé ou sel de celui-ci
BR112017017193A2 (pt) compostos herbicidas
EP3450436A4 (fr) Composé hétérocyclique condensé
EP3438103A4 (fr) Composé de griséofulvine
EP3533799A4 (fr) Composé
MA47129A (fr) Sel de composé pipéridine substitué
MA43275A (fr) Composé de pyranodipyridine
MA50937A (fr) Nouveau composé isoxazole ou sel de celui-ci
IL258791A (en) Condensed heterocyclic compound
EP3686191A4 (fr) Composé de sulfamide cristallin
EP3315493A4 (fr) Composé de phénylamino pyrimidine ou polymorphe d'un sel de ce dernier
EP3546496A4 (fr) Composé
EP3421542A4 (fr) Composé
MA42544A (fr) COMPOSÉ PYRROLO[2,3-d]PYRIMIDINE OU UN SEL DE CELUI-CI